Every human life is precious and sacred. One who saves a life it is as if he or she has saved the whole of humanity. (Al Quran 5:32/33)
Source: NBC News
By Erika Edwards
Trials in the U.S. continue and are expected to be finished in the spring.
The Maryland-based biotech company Novavax reported Thursday that its experimental Covid-19 vaccine is more than 96 percent effective in preventing mild and severe illness.
The results are from the company’s Phase 3 clinical trial, which was conducted in the U.K. Novavax’s trials in the U.S. and South Africa continue, and the company cannot apply for emergency use authorization in the U.S. until the American trials are complete.
“We are very encouraged by the data,” Stanley Erck, Novavax’s president and CEO, said in a statement.
The U.K. trial included more than 15,000 adults. More than a quarter were 65 or older, an age group that is generally considered to be at higher risk for complications of Covid-19.
The two-dose vaccine was found to be more than 96 percent effective against earlier strains of the virus circulating in the U.K., putting it on par with vaccines already in use from Moderna and Pfizer-BioNTech.
Effectiveness was slightly lower — around 86 percent — against the more contagious B.1.1.7 variant, which was first identified in the U.K. The variant has already been detected in nearly half of U.S. states, and the Centers for Disease Control and Prevention has predicted that it will be the predominant variant by the end of the month.
The Novavax vaccine was also 100 percent effective against the most severe forms Covid-19, regardless of the variant — much like the other vaccines in use in the U.S.